INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Public company

TBPHTheravance Biopharma, Inc.

CIK 0001583107

EDGAR filingsOpen in network
Disclosed transactions43
Buys / sells0 / 9
Max Insider Score21
Connections6with evidence

TBPH · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
2
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
150.0K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Gray SusannahDirector · Sep 24, 2026
  • ← Insider ofevidence
    Farnum RhondaSVP, COMM & MEDICAL AFFAIRS · Nov 24, 2025
  • ← Insider ofevidence
    Miller AineSVP, DEV & HEAD OF IRE OFFICE · Nov 24, 2025
9
MA
Miller AineSVP, DEV & HEAD OF IRE OFFICE
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D
—
96.7K sh
Sep 23, 2026
Sep 24, 2026
traded Sep 23, 2026
+1d
SEC FORM 4

Evidence

9
MA
Miller AineSVP, DEV & HEAD OF IRE OFFICE
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
37.5K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
223.9K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
107.8K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
SA
Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
108.4K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
SA
Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
23.4K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

2
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
124.4K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

2
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
89.1K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
6,009 sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
42.1K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
32.7K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
22.0K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
23.6K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

21
MA
Miller AineSVP, DEV & HEAD OF IRE OFFICE
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
93.1K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
13.4K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
24.3K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
23.4K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
SA
Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
205.0K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

1
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$113K
6,657 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

1
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$57K
3,328 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

1
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$57K
3,329 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

12
SA
Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
TBPHTheravance Biopharma, Inc.
Tax withholding
F$137K
8,112 sh
Aug 20, 2026Aug 24, 2026
traded Aug 20, 2026
+4dSEC FORM 4

Evidence

5
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Tax withholding
F$96K
5,667 sh
Aug 20, 2026Aug 24, 2026
traded Aug 20, 2026
+4dSEC FORM 4

Evidence

12
MA
Miller AineSVP, DEV & HEAD OF IRE OFFICE
TBPHTheravance Biopharma, Inc.
Tax withholding
F$106K
6,258 sh
Aug 20, 2026Aug 24, 2026
traded Aug 20, 2026
+4dSEC FORM 4

Evidence

12
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Tax withholding
F$135K
7,952 sh
Aug 20, 2026Aug 24, 2026
traded Aug 20, 2026
+4dSEC FORM 4

Evidence

13
MA
Miller AineSVP, DEV & HEAD OF IRE OFFICE
TBPHTheravance Biopharma, Inc.
Grant or award
A—
18.8K sh
Jun 19, 2026Jun 23, 2026
traded Jun 19, 2026
+4dSEC FORM 4

Evidence

12
SA
Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
TBPHTheravance Biopharma, Inc.
Tax withholding
F$143K
8,670 sh
May 20, 2026May 22, 2026
traded May 20, 2026
+2dSEC FORM 4

Evidence

12
MA
Miller AineSVP, DEV & HEAD OF IRE OFFICE
TBPHTheravance Biopharma, Inc.
Tax withholding
F$113K
6,827 sh
May 20, 2026May 22, 2026
traded May 20, 2026
+2dSEC FORM 4

Evidence

12
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Tax withholding
F$146K
8,829 sh
May 20, 2026May 22, 2026
traded May 20, 2026
+2dSEC FORM 4

Evidence

8
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$217K
15.5K sh
Mar 16, 2026Mar 18, 2026
traded Mar 16, 2026
+2dSEC FORM 4

Evidence

4
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$108K
7,766 sh
Mar 16, 2026Mar 18, 2026
traded Mar 16, 2026
+2dSEC FORM 4

Evidence

4
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$108K
7,767 sh
Mar 16, 2026Mar 18, 2026
traded Mar 16, 2026
+2dSEC FORM 4

Evidence

19
MA
Miller AineSVP, DEV & HEAD OF IRE OFFICE
TBPHTheravance Biopharma, Inc.
Tax withholding
F$331K
16.9K sh
Feb 20, 2026Feb 24, 2026
traded Feb 20, 2026
+4dSEC FORM 4

Evidence

19
SA
Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
TBPHTheravance Biopharma, Inc.
Tax withholding
F$406K
20.7K sh
Feb 20, 2026Feb 24, 2026
traded Feb 20, 2026
+4dSEC FORM 4

Evidence

19
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Tax withholding
F$410K
20.8K sh
Feb 20, 2026Feb 24, 2026
traded Feb 20, 2026
+4dSEC FORM 4

Evidence

15
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$291K
15.5K sh
Dec 3, 2025Dec 5, 2025
traded Dec 3, 2025
+2dSEC FORM 4

Evidence

8
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$146K
7,766 sh
Dec 3, 2025Dec 5, 2025
traded Dec 3, 2025
+2dSEC FORM 4

Evidence

8
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$146K
7,767 sh
Dec 3, 2025Dec 5, 2025
traded Dec 3, 2025
+2dSEC FORM 4

Evidence

19
SA
Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
TBPHTheravance Biopharma, Inc.
Tax withholding
F$333K
18.6K sh
Nov 20, 2025Nov 24, 2025
traded Nov 20, 2025
+4dSEC FORM 4

Evidence

12
MA
Miller AineSVP, DEV & HEAD OF IRE OFFICE
TBPHTheravance Biopharma, Inc.
Tax withholding
F$125K
6,989 sh
Nov 20, 2025Nov 24, 2025
traded Nov 20, 2025
+4dSEC FORM 4

Evidence

12
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Tax withholding
F$162K
9,060 sh
Nov 20, 2025Nov 24, 2025
traded Nov 20, 2025
+4dSEC FORM 4

Evidence

19
GA
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
TBPHTheravance Biopharma, Inc.
Tax withholding
F$341K
19.0K sh
Nov 20, 2025Nov 24, 2025
traded Nov 20, 2025
+4dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY · Nov 24, 2025
  • ← Insider ofevidence
    Sawaf AzizSVP & CHIEF FINANCIAL OFFICER · Nov 24, 2025